{"id":23087,"date":"2021-05-27T17:02:16","date_gmt":"2021-05-27T16:02:16","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&#038;p=23087"},"modified":"2021-06-09T11:55:36","modified_gmt":"2021-06-09T10:55:36","slug":"rebecca-gilbert-aan-2021-update-on-clinical-trials-in-parkinsons-and-huntingtons-diseases","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/parkinsons-disease\/conference-hub\/rebecca-gilbert-aan-2021-update-on-clinical-trials-in-parkinsons-and-huntingtons-diseases\/","title":{"rendered":"Rebecca Gilbert AAN, 2021: Update on Clinical Trials in Parkinson\u2019s and Huntington\u2019s Diseases"},"content":{"rendered":"<p>We were pleased to meet with one of our valued Editorial Board Members, <strong>Rebecca Gilbert<\/strong>, MD, PhD (American Parkinson Disease Association, Staten Island, NY, USA) to discuss highlights from the AAN session entitled \u2018Update on Clinical Trials in Parkinson\u2019s and Huntington\u2019s Diseases\u2019 presented at the American Academy of Neurology Virtual Annual Meeting 2021.<\/p>\n<p><strong>Questions<\/strong>:<\/p>\n<ol>\n<li>In terms of disease-modifying interventions in Parkinson\u2019s disease (PD), what have been the most exciting clinical trial findings in the last year? (0:15)<\/li>\n<li>What criteria should be used to identify patients who may benefit most from PD disease modifying interventions? (4:05)<\/li>\n<li>Could you give us a brief overview of recently completed and on-going clinical trials in Huntington\u2019s disease? (5:52)<\/li>\n<li>Following the recent decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in HD, what does the future hold for huntington-lowering as a potential treatment approach? (8:04)<\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>: Rebecca Gilbert has nothing to disclose in relation to this video.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview was conducted by Katey Gabrysch. Filmed as a highlight of AAN Annual Virtual Meeting 2021<\/p>\n<p><em><strong>Filmed as a highlight of AAN Annual Virtual Meeting 2021.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We were pleased to meet with one of our valued Editorial Board Members, Rebecca Gilbert, MD, PhD (American Parkinson Disease Association, Staten Island, NY, USA) to discuss highlights from the AAN session entitled \u2018Update on Clinical Trials in Parkinson\u2019s and Huntington\u2019s Diseases\u2019 presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: In [&hellip;]<\/p>\n","protected":false},"featured_media":23083,"template":"","class_list":["post-23087","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-parkinsons-disease","vocabulary_1-neurodegenerative-diseases","video_categories-aan-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/23087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":1,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/23087\/revisions"}],"predecessor-version":[{"id":23088,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/23087\/revisions\/23088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/23083"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=23087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}